Helix BioPharma Corp. declare processing of type 15F to stop SEC Reporting Obligations

Helix BioPharma Corp. declare processing of type 15F to stop SEC Reporting Obligations

AURORA, ON- Helix BioPharma Corp. , a biopharmaceutical business developing treatment prospects for the avoidance and therapy of malignant tumors, now announced that it’ll document a Form 15F with all the US Securities and swap payment (the “SEC”) with all the goal of terminating enrollment of its popular provides under segment 12(g) for the usa Securities trade operate of 1934, as revised (the “swap work”) and terminating their revealing obligations for all of their authorized securities under point 15(d) of the swap Act.

As formerly announced, Helix offers voluntarily delisted its common provides from your NYSE MKT. On Summer 9, 2012, Helix registered a Form 25 making use of the SEC to start the voluntary delisting, which turned successful on July 19, 2012. On July 18, 2012, Helix registered a Post-Effective modification to their enrollment declaration on version F-10 with all the SEC, the removal of from registration all unsold securities.

Upon putting some type 15F filing, Helix’s revealing responsibilities with all the SEC, such as the responsibility to file records on version 20-F and furnish data on type 6-K, will right away be supported. Helix anticipates that its revealing requirements can be terminated good three months after completing the shape 15F making use of SEC. Helix was up-to-date with its revealing needs under the trade work. Continue reading Helix BioPharma Corp. declare processing of type 15F to stop SEC Reporting Obligations